Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The search for biomarkers to aid accurate diagnosis and predict progression has become a major research goal. Creative Biolabs has developed a novel in silico methodology by facilitating the data integration and analysis for the early identification of novel disease-related biomarkers. Creative Biolabs is committed to providing overall solutions for Immune Biomarker Discovery, focusing on innovative research. Our R&D scientific team has conducted many in silico biomarker discovery projects during the past few years. We are more than happy to share our experience and help our customers with biomarker development.
In the past few years, a remarkable transformation has begun to evolve in the biomarker field. The most widely used strategy for biomarker discovery is predicated on the identification of potential candidate biomarkers using knowledge of disease processes followed by validation, comparing healthy control to affected subjects. In silico analysis of publicly available gene expression data is an efficient way. Comprehensive high-throughput genomic data are increasingly applied to human cancers in an attempt to discover predictors of clinical outcome. These databases provide an unprecedented opportunity to rapidly assess almost any mRNA expression-based biomarker separately in silico. Studies that used to require many years to be completed for immunohistochemistry (IHC)-based markers can now be completed in a few weeks by a well-trained investigator using basic bioinformatics methods.
Fig.1 Big data-driven approach. (Wooden, 2017)
Creative Biolabs applies an informatics approach through the utilization of in silico data-driven biomarker discovery that would enable a comprehensive analysis of a body of information. Firstly, an in silico molecular disease model can be constructed. Next, biomarker candidates that are dysregulated in the disease of interest are identified with this model and our efficient biomarker optimization software systems. Then, our seasoned scientists will assess the biomarker candidates identified by immunodetection methods as the clients required.
By applying our staff's experience and a proven system, Creative Biolabs continues to serve our clients with professionalism and expertise in in silico biomarker discovery. For more detailed information, please feel free to contact us or directly send us an inquiry.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
